Medexus Pharmaceuticals (TSE:MDP) Given New C$6.25 Price Target at Ventum Financial

Medexus Pharmaceuticals (TSE:MDP) had its price objective boosted by Ventum Financial from C$5.00 to C$6.25 in a research note issued to investors on Thursday,BayStreet.CA reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on MDP. Raymond James raised shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price on the stock in a report on Wednesday, January 8th. Stifel Nicolaus raised their price target on Medexus Pharmaceuticals from C$4.50 to C$6.00 in a report on Thursday. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, January 22nd. Finally, Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Two analysts have rated the stock with a buy rating and five have given a strong buy rating to the stock. According to MarketBeat, Medexus Pharmaceuticals has an average rating of “Strong Buy” and an average price target of C$6.13.

Medexus Pharmaceuticals Stock Down 0.2 %

TSE:MDP opened at C$3.99 on Thursday. The stock’s 50 day moving average price is C$3.41 and its two-hundred day moving average price is C$2.77. Medexus Pharmaceuticals has a twelve month low of C$1.47 and a twelve month high of C$5.56. The firm has a market capitalization of C$97.87 million, a price-to-earnings ratio of 79.80 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.